Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study
Cancer · 2026
DOI: 10.1002/cncr.70263 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2026. Verfasst von Rachel E Aubrey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Nerve Sheath Neoplasms, Neurofibrosarcoma, Sarcoma. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with a 5‐year survival rate of approximately 50%, secondary to their metastatic potential and resistance to therapy. MPNSTs can arise sporadically, as a late toxicity from therapeutic radiotherapy, or in patients with neurofibromatosis type 1 (NF1). Prior studies have demonstrated conflicting results regarding the prognosis of NF1 associated MPNST compared to non‐NF1 associated MPNST (NF0). The authors hypothesized that NF1‐associated MPNSTs metastasize at a higher rate and are therefore associated with worse clinical outcomes.
Methods
The authors collected data from 166 MPNST patients included in the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database. Of these, 54 had NF1. Patient demographics, overall survival (OS), cumulative incidence of progression or relapse (CIPR), and cumulative incidence of disease metastasis (CIDM) were assessed.
Results
Patients with NF1 were younger ( p < .001) and had larger tumors at MPNST diagnosis ( p < .001). Two‐year OS was lower, and CIPR and CIDM were higher in NF1‐associated compared to NF0 MPNST. NF1 status, stage at diagnosis, tumor size, and positive surgical margins were adversely correlated to OS. Tumor location was an adverse prognostic factor for CIPR, and tumor size was the only adverse predictor for the CIDM in patients who underwent surgery.
Conclusion
In summary, this study suggests that patients with NF1‐associated MPNSTs experience worse outcomes. NF1 associated MPNSTs were larger and arose in locations less amenable to negative (R0) resections. Among resectable tumors, CIDM, the primary driver of survival in patients initially diagnosed with localized disease, was correlated to tumor size but not NF1 status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Department of Biostatistics, University Health Network, Toronto, Ontario, Canada.
- Division of Orthopaedic Surgery, Department of Surgery, Sinai Health System, Toronto, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID-Profile: Rachel E Aubrey, Anna T Santiago, Anthony M Griffin
Zitieren
APA
Aubrey, R. E., Psarianos, P., Santiago, A. T., Griffin, A. M., Ferguson, P. C., Gupta, A. A., Peretz Soroka, H., & Shultz, D. B. (2026). Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study. Cancer. https://doi.org/10.1002/cncr.70263
Vancouver
Aubrey RE, Psarianos P, Santiago AT, Griffin AM, Ferguson PC, Gupta AA, et al. Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study. Cancer. 2026. doi:10.1002/cncr.70263
BibTeX
@article{Aubrey2026,
author = {Aubrey, Rachel E and Psarianos, Pamela and Santiago, Anna T and Griffin, Anthony M and Ferguson, Peter C and Gupta, Abha A and Peretz Soroka, Hagit and Shultz, David B},
title = {Outcomes following definitive treatment of malignant peripheral nerve sheath tumor are significantly worse for patients with neurofibromatosis type 1: A Canadian Sarcoma Research and Clinical Collaboration study},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70263}
}
EUVIMED